These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33974243)

  • 1. Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis.
    Piaserico S; Conti A; Messina F; Meneguzzo A; Odorici G; Bellinato F; Gisondi P
    BioDrugs; 2021 Jul; 35(4):469-471. PubMed ID: 33974243
    [No Abstract]   [Full Text] [Related]  

  • 2. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis.
    Griffiths CEM; Thaçi D; Gerdes S; Arenberger P; Pulka G; Kingo K; Weglowska J; ; Hattebuhr N; Poetzl J; Woehling H; Wuerth G; Afonso M
    Br J Dermatol; 2017 Apr; 176(4):928-938. PubMed ID: 27787890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GP2015: An Etanercept Biosimilar.
    Deeks ED
    BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study.
    Gerdes S; Thaçi D; Griffiths CEM; Arenberger P; Poetzl J; Wuerth G; Afonso M; Woehling H
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):420-427. PubMed ID: 28960486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).
    Hofmann HP; Kronthaler U; Fritsch C; Grau R; Müller SO; Mayer R; Seidl A; Da Silva A
    Expert Opin Biol Ther; 2016 Oct; 16(10):1185-95. PubMed ID: 27463856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
    Tarallo M; Onishchenko K; Alexopoulos ST
    J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
    [No Abstract]   [Full Text] [Related]  

  • 8. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4).
    Scherlinger M; Langlois E; Germain V; Schaeverbeke T
    Semin Arthritis Rheum; 2019 Apr; 48(5):927-932. PubMed ID: 30093238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study.
    Tweehuysen L; Huiskes VJB; van den Bemt BJF; Vriezekolk JE; Teerenstra S; van den Hoogen FHJ; van den Ende CH; den Broeder AA
    Arthritis Rheumatol; 2018 Sep; 70(9):1408-1418. PubMed ID: 29609207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Egeberg A; Girolomoni G; Feldman SR; Radtke MA; Carrascosa JM; Ghil J; Keum JW; Lee J; Seo H
    J Drugs Dermatol; 2020 Mar; 19(3):316-318. PubMed ID: 32550686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study.
    Girolomoni G; Feldman SR; Emery P; Ghil J; Keum JW; Cheong SY; Hong E
    Br J Dermatol; 2018 Mar; 178(3):e215-e216. PubMed ID: 29023641
    [No Abstract]   [Full Text] [Related]  

  • 12. Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis.
    Lund T; Sand C; Gniadecki R; Thomsen SF
    Dermatol Ther; 2019 May; 32(3):e12846. PubMed ID: 30697879
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of etanercept biosimilar SB4 in maintaining low disease activity in patients with psoriatic arthritis switched from etanercept originator: an open-label one year study.
    Bonifati C; De Felice C; Lora V; Morrone A; Graceffa D
    J Dermatolog Treat; 2020 Nov; 31(7):687-691. PubMed ID: 30985223
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
    RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study.
    Giunta A; Manfreda V; Esposito M; Del Duca E; Bianchi L
    Br J Dermatol; 2019 Nov; 181(5):1078-1079. PubMed ID: 31049938
    [No Abstract]   [Full Text] [Related]  

  • 16. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis.
    Chadwick L; Zhao S; Mysler E; Moots RJ
    Curr Rheumatol Rep; 2018 Nov; 20(12):84. PubMed ID: 30411183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with the etanercept biosimilar SB4 in psoriatic patients.
    Pescitelli L; Lazzeri L; Di Cesare A; Tripo L; Ricceri F; Prignano F
    Int J Clin Pharm; 2019 Feb; 41(1):9-12. PubMed ID: 30610544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.
    von Richter O; Skerjanec A; Afonso M; Sanguino Heinrich S; Poetzl J; Woehling H; Velinova M; Koch A; Kollins D; Macke L; Wuerth G
    Br J Clin Pharmacol; 2017 Apr; 83(4):732-741. PubMed ID: 27790726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data.
    Atzeni F; Gerratana E; Bongiovanni S; Talotta R; Miceli G; Salaffi F; Sarzi-Puttini P
    Isr Med Assoc J; 2021 Jun; 23(6):344-349. PubMed ID: 34155846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects.
    Lee YJ; Shin D; Kim Y; Kang J; Gauliard A; Fuhr R
    Br J Clin Pharmacol; 2016 Jul; 82(1):64-73. PubMed ID: 26972584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.